Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
RPTX

RPTX - Repare Therapeutics Inc Stock Price, Fair Value and News

3.56USD+0.03 (+0.85%)Market Closed

Market Summary

RPTX
USD3.56+0.03
Market Closed
0.85%

RPTX Stock Price

View Fullscreen

RPTX RSI Chart

RPTX Valuation

Market Cap

151.1M

Price/Earnings (Trailing)

-3.31

Price/Sales (Trailing)

1.54

EV/EBITDA

-0.9

Price/Free Cashflow

-1.78

RPTX Price/Sales (Trailing)

RPTX Profitability

EBT Margin

-59.33%

Return on Equity

-19.7%

Return on Assets

-17.37%

Free Cashflow Yield

-56.19%

RPTX Fundamentals

RPTX Revenue

Revenue (TTM)

97.9M

Rev. Growth (Yr)

116.34%

Rev. Growth (Qtr)

301.66%

RPTX Earnings

Earnings (TTM)

-45.7M

Earnings Growth (Yr)

137.67%

Earnings Growth (Qtr)

146.96%

Breaking Down RPTX Revenue

Last 7 days

1.7%

Last 30 days

10.9%

Last 90 days

-46.3%

Trailing 12 Months

-61.4%

How does RPTX drawdown profile look like?

RPTX Financial Health

Current Ratio

8.33

RPTX Investor Care

Shares Dilution (1Y)

0.85%

Diluted EPS (TTM)

-1.1

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202497.9M000
2023111.7M91.5M71.3M51.1M
20227.8M49.2M90.5M131.8M
20212.0M3.9M5.7M7.6M
2020000135.0K

Tracking the Latest Insider Buys and Sells of Repare Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 01, 2024
zinda michael
sold
-1,910
4.66
-410
evp, chief scientific officer
Apr 01, 2024
forte steve
sold
-3,637
4.61
-789
evp, chief financial officer
Apr 01, 2024
segal lloyd mitchell
sold
-11,533
4.63
-2,491
president and ceo
Apr 01, 2024
koehler maria
sold
-1,398
4.66
-300
evp, chief medical officer
Mar 28, 2024
forte steve
sold
-3,811
4.62
-825
evp, chief financial officer
Mar 28, 2024
zinda michael
sold
-2,088
4.64
-450
evp, chief scientific officer
Mar 28, 2024
segal lloyd mitchell
sold
-12,243
4.62
-2,650
president and ceo
Mar 28, 2024
koehler maria
sold
-2,320
4.64
-500
evp, chief medical officer
Mar 27, 2024
zinda michael
sold
-2,079
4.62
-450
evp, chief scientific officer
Mar 27, 2024
forte steve
sold
-3,811
4.62
-825
evp, chief financial officer

1–10 of 50

Which funds bought or sold RPTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 17, 2024
Artal Group S.A.
unchanged
-
-1,813,000
3,297,000
0.08%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-40.45
-127,817
79,759
-%
May 15, 2024
PDT Partners, LLC
new
-
141,677
141,677
0.01%
May 15, 2024
Tower Research Capital LLC (TRC)
added
1,888
17,267
18,727
-%
May 15, 2024
Aquilo Capital Management, LLC
unchanged
-
-1,640,170
2,982,710
2.24%
May 15, 2024
Deep Track Capital, LP
reduced
-10.3
-9,203,680
12,643,300
0.36%
May 15, 2024
Blue Owl Capital Holdings LP
unchanged
-
-8,087,270
14,707,000
2.94%
May 15, 2024
Corton Capital Inc.
added
66.03
14,478
217,710
0.08%
May 15, 2024
Oracle Alpha Inc.
added
58.54
2,058
91,760
0.16%
May 15, 2024
Opaleye Management Inc.
new
-
318,212
318,212
0.07%

1–10 of 48

Are Funds Buying or Selling RPTX?

Are funds buying RPTX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own RPTX
No. of Funds

Unveiling Repare Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
blue owl capital holdings lp
7.41%
3,122,499
SC 13G
Feb 14, 2024
deep track capital, lp
7.10%
2,992,731
SC 13G/A
Feb 14, 2024
redmile group, llc
5.1%
2,148,748
SC 13G/A
Jan 29, 2024
ark investment management llc
6.70%
2,821,560
SC 13G/A
Nov 17, 2023
biotechnology value fund l p
12.6%
5,309,432
SC 13D/A
Nov 03, 2023
biotechnology value fund l p
11.1%
4,662,402
SC 13D
Feb 14, 2023
biotechnology value fund l p
10.6%
4,443,423
SC 13G/A
Feb 14, 2023
redmile group, llc
6.4%
2,684,396
SC 13G/A
Feb 14, 2023
price t rowe associates inc /md/
0.1%
26,894
SC 13G/A
Feb 14, 2023
deep track capital, lp
6.50%
2,727,606
SC 13G/A

Recent SEC filings of Repare Therapeutics Inc

View All Filings
Date Filed Form Type Document
May 07, 2024
10-Q
Quarterly Report
May 07, 2024
8-K
Current Report
Apr 26, 2024
8-K
Current Report
Apr 26, 2024
ARS
ARS
Apr 26, 2024
DEF 14A
DEF 14A
Apr 26, 2024
DEFA14A
DEFA14A
Apr 01, 2024
4
Insider Trading
Apr 01, 2024
4
Insider Trading
Apr 01, 2024
4
Insider Trading
Apr 01, 2024
4
Insider Trading

Peers (Alternatives to Repare Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
50.9B
6.8B
28.49% 6.05%
-8.53
7.44
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
18.9B
2.0B
2.79% -21.33%
-56.9
9.43
75.20% 68.82%
14.7B
2.5B
-14.30% -15.94%
71.65
5.96
13.74% 186.89%
12.8B
3.8B
8.33% -10.25%
17.2
3.4
8.58% 129.81%
MID-CAP
5.6B
107.9M
20.58% 115.45%
-10.31
48.09
54.84% -28.31%
5.0B
524.1M
-13.99% -52.79%
-12.02
9.57
394.93% 39.61%
3.6B
251.0M
9.96% -0.29%
-12.28
14.5
73.58% -86.73%
3.1B
240.7M
9.94% -31.73%
-6.53
12.77
-1.03% -213.43%
2.4B
813.8M
-14.08% -36.34%
-1.4K
3
56.43% 98.83%
SMALL-CAP
1.9B
411.3M
3.06% 35.16%
29.91
4.73
60.38% -34.49%
1.8B
996.6M
233.93% 75.07%
-4.58
1.83
-26.66% 65.49%
480.9M
881.7K
21.10% 351.81%
-14.25
481.06
-77.61% 33.36%
310.9M
4.9M
8.40% 53.85%
-2.49
63.89
-54.97% 48.23%
17.1M
2.1M
4.76% 108.64%
-0.74
7.61
-13.45% 69.54%

Repare Therapeutics Inc News

Latest updates
Yahoo Finance • 12 May 2024 • 12:02 pm
Simply Wall St • 09 May 2024 • 07:00 am
TipRanks • 07 May 2024 • 09:10 pm
Investing.com • 01 Apr 2024 • 07:00 am
CNN • 4 months ago

Repare Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Revenue301.7%52,404,00013,047,0002,159,00030,249,00024,223,50018,198,000112,545,00056,476,500408,0006,877,000278,000279,000166,000-
Operating Expenses-5.3%41,588,00043,914,00040,577,00042,507,00040,359,00037,830,00039,146,00039,413,00035,237,00035,611,00031,957,00026,946,00021,746,00017,212,000
  S&GA Expenses-100.0%-8,648,0007,868,0008,719,0008,529,0007,939,0007,904,0007,938,0008,779,0007,639,0006,596,0006,741,0005,237,0004,795,000
  R&D Expenses-6.5%32,970,00035,266,00032,709,00033,788,00031,830,00029,891,00031,242,00031,475,00026,458,00027,972,00025,361,00020,205,00016,509,00012,417,000
EBITDA Margin71.8%-0.54-1.92-1.240.25-0.06-0.08-0.26-2.67-15.28-14.06-16.59-19.99--
Income Taxes231.1%629,000190,000-16,299,0003,110,0003,616,00015,028,00054,00033,00032,000-412,000-708,000-421,000-137,000-1,554,000
Earnings Before Taxes149.5%13,791,000-27,840,000-35,178,000-8,836,000-31,325,000-16,630,00075,515,000-38,060,000-34,725,000-28,702,000-31,600,000-26,730,000-21,554,000-16,817,000
EBT Margin70.6%-0.59-2.02-1.290.20-0.09-0.11-0.29-2.71-15.53-14.29-16.87-20.36--
Net Income147.0%13,162,000-28,030,000-18,879,000-11,946,000-34,941,000-31,658,00075,461,000-38,093,000-34,757,000-28,290,000-30,892,000-26,309,000-21,417,000-15,263,000
Net Income Margin74.5%-0.47-1.83-1.37-0.03-0.26-0.22-0.28-2.69-15.33-14.07-16.37-19.84--
Free Cashflow141.8%11,932,000-28,554,000-32,870,000-35,411,000-32,261,000-27,917,00087,892,000-29,762,000-30,493,000-20,903,000-33,097,000-18,487,000--
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22019Q4
Assets3.6%263254286302336364409308337369296321339357370382103
  Current Assets4.5%25524427529232635439129031935128030932834736137799.00
    Cash Equivalents-7.2%10311110711612116015527630533426129431232634837095.00
  Net PPE-11.9%4.004.005.005.005.004.005.005.005.006.004.004.004.004.003.002.002.00
Liabilities-25.6%31.0042.0053.0056.0085.0085.0010383.0078.0080.0077.0076.0071.0070.0069.0068.0013.00
  Current Liabilities-21.8%31.0039.0049.0053.0081.0079.0062.0039.0034.0035.0023.0023.0012.0011.0010.0010.004.00
Shareholder's Equity9.4%232212233245251280306226259288218245268287301314-
  Retained Earnings3.9%-319-333-305-286-274-239-207-283-245-210-181-151-124-103-88.09-74.34-49.94
  Additional Paid-In Capital6.2%66.0062.0056.0049.0043.0037.0032.0027.0023.0018.0014.0011.008.006.005.004.004.00
Shares Outstanding0.6%42.0042.0042.0042.0042.0042.0042.0042.0042.0042.0037.0037.00-----
Float----383---455---812---704-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q2
Cashflow From Operations142.4%11,932-28,156-32,870-34,346-31,786-29,63788,158-28,193-30,006-20,738-32,773-18,058-14,227-12,947-20,10436,684-9,717---
  Share Based Compensation1.8%6,4756,3596,3776,2656,0625,1385,0534,7454,7553,8963,6933,1832,0571,006871389271---
Cashflow From Investing-163.7%-20,31631,87924,49828,350-6,68634,058-208,930-1,309403-398-389-117-772-9,247-473-13.00-30.00---
Cashflow From Financing257.1%37510528440.0041316526920524194,562363449183289-1,695249,026222---
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

RPTX Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue:  
Collaboration agreements$ 52,404$ 5,678
Operating expenses:  
Research and development, net of tax credits32,97031,830
General and administrative8,6188,529
Total operating expenses41,58840,359
Income (loss) from operations10,816(34,681)
Other income (expense), net  
Realized and unrealized gain (loss) on foreign exchange31(56)
Interest income2,9683,427
Other expense(24)(15)
Total other income, net2,9753,356
Income (loss) before income taxes13,791(31,325)
Income tax expense(629)(3,616)
Net income (loss)13,162(34,941)
Unrealized (loss) gain on available-for-sale marketable securities(141)193
Total other comprehensive (loss) income(141)193
Comprehensive income (loss)$ 13,021$ (34,748)
Net income (loss) per share attributable to common shareholders--basic$ 0.31$ (0.83)
Net income (loss) per share attributable to common shareholders--diluted$ 0.3$ (0.83)
Weighted-average common shares outstanding-basic42,234,00142,040,674
Weighted-average common shares outstanding-diluted44,024,19842,040,674

RPTX Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
CURRENT ASSETS:  
Cash and cash equivalents$ 103,217$ 111,268
Marketable securities133,784112,359
Income tax receivable10,82910,813
Other current receivables3,3774,499
Prepaid expenses3,4634,749
Total current assets254,670243,688
Property and equipment, net3,7144,215
Operating lease right-of-use assets2,7633,326
Income tax receivable1,6302,276
Other assets307396
TOTAL ASSETS263,084253,901
CURRENT LIABILITIES:  
Accounts payable6,8252,400
Accrued expenses and other current liabilities20,45424,057
Operating lease liability, current portion2,2182,400
Deferred revenue, current portion1,07310,222
Total current liabilities30,57039,079
Operating lease liability, net of current portion5611,010
Deferred revenue, net of current portion01,730
TOTAL LIABILITIES31,13141,819
SHAREHOLDERS’ EQUITY  
Preferred shares, no par value per share; unlimited shares authorized as of March 31, 2024 and December 31, 2023, respectively; 0 shares issued and outstanding as of March 31, 2024, and December 2023, respectively00
Common shares, no par value per share; unlimited shares authorized as of March 31, 2024 and December 31, 2023; 42,445,406 and 42,176,041 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively486,375483,350
Additional paid-in capital65,63861,813
Accumulated other comprehensive (loss) income(113)28
Accumulated deficit(319,947)(333,109)
Total shareholders’ equity231,953212,082
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY$ 263,084$ 253,901
RPTX
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing PKMYT1 Inhibitor (RP-6306), which is under Phase ½ clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has icense and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; and Ono Pharmaceutical Co. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in St-Laurent, Canada.
 CEO
 WEBSITEreparerx.com
 INDUSTRYBiotechnology
 EMPLOYEES180

Repare Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Repare Therapeutics Inc? What does RPTX stand for in stocks?

RPTX is the stock ticker symbol of Repare Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Repare Therapeutics Inc (RPTX)?

As of Fri May 17 2024, market cap of Repare Therapeutics Inc is 151.11 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RPTX stock?

You can check RPTX's fair value in chart for subscribers.

What is the fair value of RPTX stock?

You can check RPTX's fair value in chart for subscribers. The fair value of Repare Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Repare Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RPTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Repare Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether RPTX is over valued or under valued. Whether Repare Therapeutics Inc is cheap or expensive depends on the assumptions which impact Repare Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RPTX.

What is Repare Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, RPTX's PE ratio (Price to Earnings) is -3.31 and Price to Sales (PS) ratio is 1.54. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RPTX PE ratio will change depending on the future growth rate expectations of investors.